BioCentury
ARTICLE | Clinical News

Abraxane nab-paclitaxel regulatory update

March 24, 2014 7:00 AM UTC

Specialised Therapeutics Australia Pty. Ltd. (Melbourne, Australia) said Australia's Therapeutic Goods Administration ( TGA) approved Abraxane nab-paclitaxel for the first-line treatment of metastatic pancreatic cancer in combination with gemcitabine. Abraxane is already approved in the EU and U.S. for the indication and in more than 40 countries, including the U.S., Australia and those of the EU, as second-line treatment of metastatic breast cancer. The albumin stabilized nanoparticle formulation of paclitaxel is also approved in the U.S., Argentina, Australia, Japan and New Zealand for first-line treatment of advanced non-small cell lung cancer (NSCLC). ...